Cargando…
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. In preclinical studies, SP1049C demonstrated increased efficacy compared to doxorubicin. The objectives of this first phase I study were to determine the toxicity profile, dose-limiting toxicity, m...
Autores principales: | Danson, S, Ferry, D, Alakhov, V, Margison, J, Kerr, D, Jowle, D, Brampton, M, Halbert, G, Ranson, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409484/ https://www.ncbi.nlm.nih.gov/pubmed/15150584 http://dx.doi.org/10.1038/sj.bjc.6601856 |
Ejemplares similares
-
Effect of Doxorubicin/Pluronic SP1049C on Tumorigenicity, Aggressiveness, DNA Methylation and Stem Cell Markers in Murine Leukemia
por: Alakhova, Daria Y., et al.
Publicado: (2013) -
Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion
por: Batrakova, E V, et al.
Publicado: (2001) -
Complete Sequence and Annotation of the Mycoplasma phocicerebrale Strain 1049(T) Genome
por: Frasca, Salvatore, et al.
Publicado: (2019) -
P1049: CHARACTERISTICS AND OUTCOMES OF CARDIOVASCULAR INVOLVEMENT IN ERDHEIM-CHESTER DISEASE
por: Tawfiq, Reema, et al.
Publicado: (2023) -
Phase I and pharmacokinetic study of D-verapamil and doxorubicin.
por: Bissett, D., et al.
Publicado: (1991)